Loading...
XPAR
OSE
Market cap133mUSD
Jun 12, Last price  
5.15EUR
1D
-2.65%
1Q
-18.90%
Jan 2017
-27.26%
IPO
-51.42%
Name

OSE Immunotherapeutics SA

Chart & Performance

D1W1MN
P/E
—
P/S
51.59
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.74%
Rev. gr., 5y
-38.07%
Revenues
2m
-87.83%
0004,000383,0006,682,00024,456,00025,952,00010,418,00026,306,00018,302,0002,227,000
Net income
-23m
L+29.52%
-1,436,000-250,000-2,835,000-5,584,00020,666,000-10,503,0005,490,000-4,652,000-16,555,000-16,850,000-17,760,000-23,003,000
CFO
-20m
L+8.28%
-1,393,000-236,000-1,937,000-4,614,000684,000-7,996,0001,077,0008,971,000-19,550,000-9,919,000-18,252,000-19,764,000
Earnings
Sep 24, 2025

Profile

OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.
URL
https://ose-immuno.com/
IPO date
Mar 30, 2015
Employees
67
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,227
-87.83%
18,302
-30.43%
Cost of revenue
17,158
36,543
Unusual Expense (Income)
NOPBT
(14,931)
(18,241)
NOPBT Margin
Operating Taxes
(219)
(5,694)
Tax Rate
NOPAT
(14,712)
(12,547)
Net income
(23,003)
29.52%
(17,760)
5.40%
Dividends
Dividend yield
Proceeds from repurchase of equity
11,657
6
BB yield
-13.92%
0.00%
Debt
Debt current
7,261
3,976
Long-term debt
42,430
40,817
Deferred revenue
1,000
3,586
Other long-term liabilities
429
524
Net debt
31,019
18,649
Cash flow
Cash from operating activities
(19,764)
(18,252)
CAPEX
(232)
(274)
Cash from investing activities
(507)
26
Cash from financing activities
13,324
10,267
FCF
(14,091)
(12,087)
Balance
Cash
18,672
25,620
Long term investments
524
Excess cash
18,561
25,229
Stockholders' equity
(18,827)
(32,404)
Invested Capital
88,032
110,247
ROIC
ROCE
EV
Common stock shares outstanding
19,562
18,457
Price
4.28
-35.88%
6.68
-35.07%
Market cap
83,726
-32.04%
123,203
-33.99%
EV
114,900
141,852
EBITDA
(11,460)
(14,684)
EV/EBITDA
Interest
2,269
1,372
Interest/NOPBT